Cipher Gene, a Beijing-based gene big data and precision medicine service provider, has reportedly secured RMB 100 million in a Series C financing round. The funding round was led by Chengdu Jinjiang, with participation from Zhongxi Fund and several existing investors. The capital raised will be utilized to enhance the co-construction of hospital LDT laboratories, expedite the implementation of comprehensive genetic/rare disease solutions in leading medical institutions, and intensify the research and registration of three-level birth defect prevention and control products. These efforts aim to deepen Cipher Gene’s strategic focus on the integration of precise genetic and rare disease prevention and treatment.
Established in 2015, Cipher Gene operates a third-party medical laboratory certified by CAP and holds clinical molecular genetics qualifications from the American Board of Medical Genetics and Genomics. The company also possesses a functional verification and high-throughput drug screening platform. Its portfolio encompasses genetic disease assisted diagnosis and birth defect three-level prevention and control screening products based on high-throughput sequencing, as well as services in translational medicine and drug development.- Flcube.com
